Plasma aminothiol oxidation in chronic hemodialysis patients

Kidney International

Volumn 61, Issue 2, 2002, Pages 705-716

  Himmelfarb, Jonathan ^a   McMenamin, Elizabeth ^a   McMonagle, Ellen ^a  

^a MAINE MEDICAL CENTER   (United States)

Author keywords

Cysteine; End stage renal disease; Extracellular redox system; Glutathione; Homocysteine; Oxidant stress; Uremia; Uremic toxin

Indexed keywords

AMINOTHIOL; CYSTEINE; CYSTEINYLGLYCINE; GLUTATHIONE; HOMOCYSTEINE; UREMIC TOXIN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ASSOCIATION; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LONG TERM CARE; OXIDATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN BINDING; REDUCTION; UREMIA;

EID: 0036151655     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00151.x     Document Type: Article

References (61)

1. Oxidative stress in chronic renal failure
2. Physiopathology of the oxidative stress and its implications in uremia and dialysis
3. Oxidative stress during dialysis: Effect on free radical scavenging enzyme (FRSE) activities and glutathione (GSH) concentration in granulocytes
4. An overview of haemodialysis and oxidative stress
5. A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure: Evidence of increased oxidative stress in malnourished patients
6. Oxidative stress in haemodialysis
7. Advanced oxidation protein products as a novel marker of oxidative stress in uremia
8. Detection of oxidants in uremic plasma by electron spin resonance spectroscopy
9. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors
10. Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis?
11. Oxidative stress and cardiovascular disease in hemodialysis
12. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis
13. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure
14. Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment
15. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure
16. Thiol-based antioxidants
17. Toxicity of thiols and disulphides: Involvement of free-radical species
18. Hyperhomocysteinemia, hyperfibrinogenemia and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study
19. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study
20. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology and potential relationship to arteriosclerotic outcomes
21. Reduced, free, and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure
22. Concentrations of total homocysteine in plasma in chronic renal failure
23. Effects of high-dose folic acid and pyridoxine on plasma and erythrocyte sulfur amino acids in hemodialysis patients
24. Effects of methionine loading on plasma and erythrocyte sulphur amino acids and sulph-hydryls before and after co-factor supplementation in haemodialysis patients
25. Total, free, and protein-bound sulphur amino acids in uraemic patients
26. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
27. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
28. Homocysteine: A sulph'rous fire
29. The oxidant stress of hyperhomocysteinemia
30. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells
31. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis
32. Homocysteine and thrombotic disease
33. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model
34. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia
35. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis
36. Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project
37. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease
38. Plasma homocysteine levels and mortality in patients with coronary artery disease
39. Intracoronary infusion of reduced glutathione improves endothelial vasomotor response to acetylcholine in human coronary circulation
40. Serum glutathione in adolescent males predicts parental coronary heart disease
41. Glutathione-related antioxidant defenses in human atherosclerotic plaques
42. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine and glutathione in human plasma
43. Redox state of glutathione in human plasma
44. The antioxidants of human extracellular fluids
45. Epidemiology of cardiovascular disease in chronic renal disease
46. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients
47. Homocysteine metabolism
48. Blood glutathione and cysteine changes in cardiovascular disease
49. Differences between cysteine and homocysteine in the induction of deoxyribose degradation and DNA damage
50. The effect of cysteine on the auto-oxidation of homocysteine
51. Oxidation of low density lipoprotein by thiols: Superoxide-dependent and -independent mechanisms
52. Thiols as a measure of plasma redox status in healthy subjects and in patients with renal or liver failure
53. Low whole blood and erythrocyte levels of glutathione in hemodialysis and peritoneal dialysis patients
54. Anemia and chronic renal failure: The possible role of oxidative state of glutathione
55. Plasma reduced homocysteine concentrations are increased in end-stage renal disease
56. Reduced, oxidized and protein-bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status - A possible element of the extracellular antioxidant defense system
57. Redox status and protein binding of plasma aminothiols during the transient hyperhomocysteinemia that follows homocysteine administration
58. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with homocystinuria
59. Dynamic relation between reduced, oxidized and protein-bound homocysteine and other thiol components in plasma during methionine loading in healthy men
60. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with hyperhomocysteinemia due to cobalamin deficiency
61. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm